Bionomics Share Price Surges by 62.5% after PTSD Trial News

At time of writing, shares of Bionomics Ltd [ASX:BNO] are up by 62.5%, to 19.5 cents per share.

Why did Bionomics Ltd share price push higher?

Bionomics announced additional analysis conducted by Pharmetheus AB, showing a statistically significant response in the Phase 2 PTSD Trial (referred to as the RESTORE trial). The exposure-response analysis tested patients’ blood levels to the company’s drug, regardless of the administered dose. The analysis showed a reduction in total PTSD symptoms, as measured by total CAPS-5. That’s the endpoint mandated by the US Food & Drug Administration (FDA) for PTSD trials.

What’s up next for Bionomics Ltd?

The share price increased on the news:

Bionomics Share Price
Bionomics Share Price

Source: CommSec

Bionomics has traded sideways since September, when it decreased by more than 50%. The company announced that its trial didn’t meet the primary end point at the time. Of course, that’s changed now and the share price went up on the news today. In my opinion, the share price could hold this level for the time being, until the company advances through to the next stage of its trials.

I believe Bionomics could become a billion-dollar company, if it can get through its trial process and sell its drug ― BNC210. BNC210 aims to treat the large population of patients suffering with post-traumatic stress disorder (PTSD) worldwide. I see a need for a safe and effective treatment in the market.

Dr Errol De Souza, Executive Chairman of Bionomics, told the market today:

Bionomics had a solid scientific rationale for evaluating BNC210 in PTSD, based on its mechanism of action, and this has been borne out by this further analysis. At the time of the topline data announcement of 2 October 2018, the results of the complex and time-consuming drug exposure analyses were not available and could not have readily been foreseen. The results of the further analysis are meaningful for future development of BNC210 and they support its continued development for PTSD, as well as other indications, and our ongoing partnering activities.

Bionomics has discovered an improved solid dose formulation of BNC210. It has the potential to overcome the ‘food effect’ by using a liquid formulation; as such, patients might not need to take the drug with food. It’s anticipated the solid dose formulation will be used in any future PTSD trials.

The company intends to seek FDA guidance on the next steps for BNC210, including the design of a further trial and whether BNC210 is eligible for Fast Track designation. If this is approved by the FDA, the share price could surge higher in my opinion.


Jason Stevenson,
Resources Analyst, Markets & Money

Jason Stevenson is Markets & Money’s resource analyst. He shares over a decade’s worth of investing and trading experience across resource stocks and commodity futures and options. He originally studied accounting and finance at Curtin University, where he was awarded a first-class honours degree. His professional background stems across high-net-worth, top tier accounting (corporate finance, tax and auditing), and sell-side equities research. Before joining the team at Markets and Money, Jason worked at boutique firms which advised fund managers and high-net-worth clients on where to invest. Whether it’s gold, crude oil, copper or an obscure metal like vanadium, you can rely on an in-depth analysis in Markets and Money. Jason also brings you extensive macro, political and geopolitical analysis from around the world. He leaves no stone unturned when it comes to telling the truth. Jason is also the lead analyst of Gold Stock Trader, a premium service for investors serious about precious metal stocks. Websites and financial e-letters Jason writes for:

Leave a Reply

Your email address will not be published. Required fields are marked *

Markets & Money